Chugai Pharmabody Research

Chugai Pharmabody Research (CPR) was established in Singapore as a wholly-owned subsidiary of Chugai Pharmaceutical Co., Ltd. ("Chugai"), Japan' s leading biopharmaceutical company, in January 2012. CPR conducts research on the generation of new antibody drug clinical candidates focusing on high value First-in-Class and Best-in-Class antibodies for a variety of targets, and utilizing Chugai' s proprietary innovative antibody engineering technologies such as the "Recycling Antibody" technology and the "Sweeping Antibody" technology.